- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01448265
Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter (CRYO-MAP)
Background: Atrial fibrillation (AF) is the most frequent sustained cardiac arrhythmia, impairs quality of life and increases stroke risk and mortality. Recent clinical experience with the Arctic Front™ cryoballoon ablation catheter system (Medtronic) suggests that it can be used to isolate the pulmonary veins (PVs) safely and effectively in patients with AF, thereby eliminating the recurrence of AF.
Hypothesis: Our hypotheses are (1) that visualization of real-time pulmonary vein conduction during cryoballoon ablation of atrial fibrillation using a novel spiral circumferential mapping catheter (Achieve™) is feasible and safe, and (2) that procedure and fluoroscopy times decrease with experience.
Objective: The purpose of this study is to assess safety, feasibility, and a learning curve associated with cryoballoon catheter ablation using a novel circular mapping catheter (Achieve™, Medtronic) inserted through the lumen of the cryoballoon in patients with symptomatic paroxysmal atrial fibrillation.
The primary goal is to evaluate successful pulmonary vein isolation using the Achieve™ mapping catheter. The reduction of procedure and fluoroscopy times during the first 40 patients treated with this approach will be analyzed to evaluate a potential learning curve upon introduction of the technique.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A total of 40 patients scheduled for a first ablation of paroxysmal AF will be included. All study subjects will undergo cryoablation using the 28 mm Arctic Front™ Cryoablation Catheter. A double transseptal approach will be followed in all study patients, allowing for use of regular guide wire and circular mapping catheter, respectively, if required.
Use of the 20 mm Achieve™ circular mapping catheter is preferred. The 15 mm AchieveTM catheter may be used at the physician's discretion. If stable balloon positions cannot be obtained, the Achieve™ catheter will be replaced by a regular guide wire and pulmonary vein isolation will be assessed by a circular mapping catheter (Lasso™; Biosense Webster) introduced through a second transseptal puncture. Cryoablations will be applied for 5 minutes each. Premature terminations will be allowed at the physician's discretion but should be avoided to allow for detection of late pulmonary vein isolation during cryoenergy application. Cryoballoon catheter manipulations (e.g., pull down maneuver) may be performed during energy application. During ablation of septal pulmonary veins, electrical phrenic nerve stimulation will be performed to exclude phrenic nerve palsy. If additional single point ablations are required to achieve electrical isolation of pulmonary veins, a linear cryocatheter (Freezor™ Max; Medtronic) will be used.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Heidelberg, Germany, 69120
- Department of Cardiology, University of Heidelberg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented paroxysmal atrial fibrillation
- ≥18 and ≤75 years of age
- Failure of one or more antiarrhythmic drugs
- Referral for a pulmonary vein isolation catheter ablation procedure to treat atrial fibrillation
Exclusion Criteria:
- Previous ablation of atrial fibrillation
- Documented left atrial thrombus
- Irregular pulmonary vein anatomy according to transesophageal echocardiography
- Atrial fibrillation secondary to reversible cause
- Amiodarone therapy in the previous 6 months
- Cardiac surgery within the prior 6 months
- Myocardial infarction within the previous 2 months
- Ejection fraction < 40%
- NYHA class III or IV
- Moderate to severe valvular heart disease
- Previous valve replacement
- Pacemaker or implantable cardioverter defibrillator placement in the prior 3 months
- History of stroke or TIA within the previous 12 months
- Left atrial size ≥ 50 mm
- Contraindication for anticoagulation medication
- Life expectancy of less than 12 months
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paroxysmal atrial fibrillation.
|
Cryoballoon ablation using a novel circular mapping catheter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Feasibility, defined as successful pulmonary vein isolation using the novel circular mapping catheter with the cryoballoon.
Time Frame: Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time from beginning of the freeze to conduction blockade ("time to effect").
Time Frame: Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Treatment-related adverse events.
Time Frame: Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Procedure time.
Time Frame: Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Overall fluoroscopy time and dose.
Time Frame: Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dierk Thomas, MD, Department of Cardiology, University of Heidelberg
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRYO-MAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Cryoballoon ablation.
-
Staten Island University HospitalUnknownPersistent Atrial FibrillationUnited States
-
Pentax MedicalCompletedEsophageal CancerUnited States
-
The Second Hospital of Hebei Medical UniversityCompletedPersistent Atrial FibrillationChina
-
Shanghai 10th People's HospitalNot yet recruiting
-
G.Gennimatas General HospitalUnknownAtrial Fibrillation | Heart Failure, SystolicGreece
-
Yuksek Ihtisas HospitalCompletedParoxysmal Atrial FibrillationTurkey
-
Pentax MedicalCompletedBarrett's EsophagusUnited States, Netherlands
-
Karan SarafUniversity of ManchesterWithdrawnParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Harald VerheijAcademisch Ziekenhuis Maastricht; Thorax Centrum TwenteCompleted
-
University Hospital, Gentofte, CopenhagenCompletedAtrial FibrillationDenmark